Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Minoxidil · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Topical 5% minoxidil foam formulation used twice daily |
| vehicle of 5% Minoxidl topical foam | PLACEBO_COMPARATOR | vehicel foam in twice daily application in temple and vertex region |
| 5% Minoxidil topical foam | ACTIVE_COMPARATOR | 5% Minoxidil topical in twice daily application in temple and vertex region |
| Name | Type | Description |
|---|---|---|
| minoxidil | DRUG | Topical 5% minoxidil foam, BID, for sixteen weeks |
| vehicle of 5% Minoxidil topical foam | DRUG | 1 g of vehicle topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase |
Inclusion Criteria: * presence of androgenetic alopecia with vertex pattern IIIv, IV, or V on the Norwood Hamilton Scale * Male sex, age 15 to 49, good health * Willingness to have a dot tattoo placed in the target area of the scalp during the study * Willingness to maintain normal shampooing habit...
Minoxidil is used for the treatment of androgenetic alopecia, a common form of hair loss. It is a small molecule developed by Johnson & Johnson (JNJ) and is being studied in clinical trials for this condition. The drug is applied topically as a foam and is intended to promote hair growth in affected individuals.
Minoxidil targets the hair follicles to stimulate hair growth. As a small molecule, it works by promoting blood flow to the scalp and increasing the size of hair follicles, which helps counteract the effects of androgenetic alopecia. This mechanism is being evaluated in clinical trials for its effectiveness and safety.
Minoxidil is developed by Johnson & Johnson, a pharmaceutical company traded under the ticker JNJ. The company is conducting clinical trials to evaluate the drug's effectiveness and safety for treating androgenetic alopecia. Johnson & Johnson is responsible for the development and potential commercialization of this treatment.
Minoxidil is in Phase 3 clinical development for androgenetic alopecia. It has completed two clinical trials, including a Phase 3 study with 352 participants and a Phase 2 study with 70 participants. The drug is investigational and not yet approved, as it is still undergoing clinical evaluation.
Minoxidil has been studied in two completed clinical trials. NCT00151515 is a Phase 3 study evaluating the effectiveness and safety of 5 percent Minoxidil foam in male pattern hair loss, with 352 participants in the United States. NCT01319370 is a Phase 2 study comparing Minoxidil foam to placebo foam for androgenetic alopecia, with 70 participants in Germany.
Minoxidil is a distinct treatment for androgenetic alopecia and is not the same as other hair loss medications. It is a small molecule developed by Johnson & Johnson and is being evaluated in clinical trials. Its mechanism of action and formulation as a foam differentiate it from other available treatments for hair loss.